|
||
| |||||||
|
|
Oxford, UK; 05 April 2006 – Oxford Immunotec Ltd, the T cell measurement company, has today announced the outcome of a recent study performed at the Chelsea and Westminster Hospital, London. The results of the study which were presented to the 12th Annual Conference of the British HIV Association meeting in Brighton (29th March-April 1st) confirmed that the Company’s T-SPOT.TB test is able to detect tuberculosis in HIV patients whose immune systems are severely compromised. These data confirm previously reported results from several other studies confirming that T-SPOT.TB performs well even in patients whose CD4 T cell count is less than 200 cells/μl. The study also confirmed the ability of T-SPOT.TB to be used as a ‘rule-out’ test for TB infection in HIV patients. Commenting on the reported findings, Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec said “This study confirms previously published results by other groups and firmly establishes T-SPOT.TB as the only test for latent Tuberculosis infection to have consistently demonstrated efficacy in HIV infected patients with low CD4 T cell counts”. - ENDS - Notes to editors: About Oxford Immunotec Oxford Immunotec, the T cell measurement company, is headquartered near Oxford, UK. The Company develops and sells clinical diagnostic products based on its patented T-SPOT technology, the first regulatory approved method for directly quantifying antigen-specific T cells. T-SPOT is a simple and extremely accurate method of studying a person’s cellular immune response to infection and can be applied to diagnose and monitor any major disease driven by a T cell response. About T-SPOT.TB T-SPOT.TB is an in vitro T cell measurement assay used for diagnosing TB disease and latent TB infection and the first product from Oxford Immunotec using the T-SPOT technology. The product is extremely robust and offers unrivalled and maintained sensitivity in high risk and immunocompromised patient groups. T-SPOT.TB is approved for sale in Europe and is designed to replace the 115 year old Tuberculin Skin Test. As such it offers a substantially more accurate and effective tool for controlling the spread of TB, addressing a market of £600m. Unlike the traditional Tuberculin Skin Test, the T-SPOT.TB test incorporates a positive control, allowing the user to distinguish between a genuine negative result and one which is indeterminate (ie an inconclusive result) as a result of a technical failure. T-SPOT is a registered trademark of Oxford Immunotec. For more information please contact: At Oxford Immunotec: Dr Peter Wrighton-Smith, CEO or Mr Ian Miscampbell, CFO
Oxford Immunotec
Tel: +44 (0)1235 442780 At Northbank Communications: (for Oxford Immunotec)
Lorna Watson, Senior
Account Manager
Tel: +44 (0)20 7886 8157
|
|
| ||||||||
